LSE - Delayed Quote GBp

Trellus Health plc (TRLS.L)

1.8500
0.0000
(0.00%)
At close: May 23 at 2:57:01 PM GMT+1
Loading Chart for TRLS.L
  • Previous Close 1.8500
  • Open 2.0000
  • Bid 1.7000 x --
  • Ask --
  • Day's Range 1.8000 - 2.0000
  • 52 Week Range 0.5000 - 5.4000
  • Volume 740,100
  • Avg. Volume 879,098
  • Market Cap (intraday) 2.988M
  • Beta (5Y Monthly) 2.30
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0300
  • Earnings Date May 26, 2025 - Jun 7, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Trellus Health plc provides digital chronic condition management solutions for employers and health plans. The company offers GRITT resilience-based methodology; and TrellusElevate, a proprietary HIPAA-compliant technology platform for remote telemedicine care. Its platform provides support for managing inflammatory bowel disease (IBD), including Crohn's Disease and ulcerative colitis. The company was incorporated in 2020 and is headquartered in White Plains, New York.

www.trellushealth.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: TRLS.L

View More

Performance Overview: TRLS.L

Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .

YTD Return

TRLS.L
252.38%
FTSE 100 (^FTSE)
6.67%

1-Year Return

TRLS.L
12.12%
FTSE 100 (^FTSE)
4.54%

3-Year Return

TRLS.L
90.26%
FTSE 100 (^FTSE)
16.03%

5-Year Return

TRLS.L
96.41%
FTSE 100 (^FTSE)
45.46%

Compare To: TRLS.L

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TRLS.L

View More

Valuation Measures

Annual
As of 5/23/2025
  • Market Cap

    2.99M

  • Enterprise Value

    -3.01M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    72.89

  • Price/Book (mrq)

    0.26

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -22.76%

  • Return on Equity (ttm)

    -35.08%

  • Revenue (ttm)

    55k

  • Net Income Avi to Common (ttm)

    -6.66M

  • Diluted EPS (ttm)

    -0.0300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.04M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -5.44M

Research Analysis: TRLS.L

View More

Company Insights: TRLS.L

Research Reports: TRLS.L

View More

People Also Watch